SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.22

Change

-0.04 (-15.38)%

Market Cap

N/A

Volume

4.64K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.29 (+0.37%)

USD 241.92B
AMGN Amgen Inc

-0.46 (-0.14%)

USD 173.38B
SNY Sanofi ADR

-0.02 (-0.03%)

USD 144.83B
GILD Gilead Sciences Inc

+0.23 (+0.28%)

USD 104.09B
BIIB Biogen Inc

-0.83 (-0.43%)

USD 28.36B
GRFS Grifols SA ADR

-0.07 (-0.78%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.02 (+3.76%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.14 (+12.07%)

USD 0.02B
SCLX Scilex Holding Company

-0.02 (-1.70%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.89% 15% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.89% 15% F 21% F
Trailing 12 Months  
Capital Gain -53.56% 15% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.56% 15% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.15% N/A N/A 16% F
Dividend Return -21.15% N/A N/A 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.87% N/A N/A 38% F
Risk Adjusted Return -45.14% N/A N/A 19% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector